NL8104818A - Geneesmiddel voor het behandelen van suikerziekte en werkwijze voor de toediening van het preparaat. - Google Patents

Geneesmiddel voor het behandelen van suikerziekte en werkwijze voor de toediening van het preparaat. Download PDF

Info

Publication number: NL8104818A
Authority: NL; Netherlands
Prior art keywords: biotin; insulin; patient; serum; glucose
Prior art date: 1980-10-27

Application number

NL8104818A

Other languages

English (en)

Dutch (nl)

Original Assignee

Capital Medical Ass

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1980-10-27

Filing date

1981-10-26

Publication date

1982-05-17

1981-10-26 Application filed by Capital Medical Ass filed Critical Capital Medical Ass

1982-05-17 Publication of NL8104818A publication Critical patent/NL8104818A/nl

Links

238000000034 method Methods 0.000 title claims description 28
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 9
201000010099 disease Diseases 0.000 title description 8
238000002360 preparation method Methods 0.000 title description 3
229940126601 medicinal product Drugs 0.000 title description 2
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 323
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 170
239000011616 biotin Substances 0.000 claims description 157
229960002685 biotin Drugs 0.000 claims description 157
235000020958 biotin Nutrition 0.000 claims description 151
102000004877 Insulin Human genes 0.000 claims description 85
108090001061 Insulin Proteins 0.000 claims description 85
229940125396 insulin Drugs 0.000 claims description 85
210000002966 serum Anatomy 0.000 claims description 55
206010012601 diabetes mellitus Diseases 0.000 claims description 47
229940068840 d-biotin Drugs 0.000 claims description 18
230000001419 dependent effect Effects 0.000 claims description 16
230000037396 body weight Effects 0.000 claims description 15
206010018473 Glycosuria Diseases 0.000 claims description 13
201000001421 hyperglycemia Diseases 0.000 claims description 12
230000003247 decreasing effect Effects 0.000 claims description 11
230000004044 response Effects 0.000 claims description 11
239000003814 drug Substances 0.000 claims description 7
238000007446 glucose tolerance test Methods 0.000 claims description 5
230000035780 glucosuria Effects 0.000 claims description 3
239000000825 pharmaceutical preparation Substances 0.000 claims description 3
229940127557 pharmaceutical product Drugs 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 2
239000000203 mixture Substances 0.000 claims description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 72
239000008103 glucose Substances 0.000 description 72
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 39
238000002560 therapeutic procedure Methods 0.000 description 25
239000000902 placebo Substances 0.000 description 19
229940068196 placebo Drugs 0.000 description 19
210000002700 urine Anatomy 0.000 description 19
230000000052 comparative effect Effects 0.000 description 14
239000000126 substance Substances 0.000 description 14
208000001072 type 2 diabetes mellitus Diseases 0.000 description 14
238000002474 experimental method Methods 0.000 description 12
230000007423 decrease Effects 0.000 description 8
230000000694 effects Effects 0.000 description 8
230000006698 induction Effects 0.000 description 8
238000012417 linear regression Methods 0.000 description 8
230000002485 urinary effect Effects 0.000 description 6
239000002131 composite material Substances 0.000 description 5
235000005911 diet Nutrition 0.000 description 5
230000029142 excretion Effects 0.000 description 5
239000002933 immunoreactive insulin Substances 0.000 description 5
241000700159 Rattus Species 0.000 description 4
HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 4
230000037213 diet Effects 0.000 description 4
210000004185 liver Anatomy 0.000 description 4
238000007619 statistical method Methods 0.000 description 4
238000004458 analytical method Methods 0.000 description 3
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
239000013256 coordination polymer Substances 0.000 description 3
230000006872 improvement Effects 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
230000006362 insulin response pathway Effects 0.000 description 3
238000011835 investigation Methods 0.000 description 3
208000004880 Polyuria Diseases 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
235000013339 cereals Nutrition 0.000 description 2
235000013305 food Nutrition 0.000 description 2
230000003914 insulin secretion Effects 0.000 description 2
238000005259 measurement Methods 0.000 description 2
230000004060 metabolic process Effects 0.000 description 2
210000000496 pancreas Anatomy 0.000 description 2
230000009467 reduction Effects 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
235000021411 American diet Nutrition 0.000 description 1
235000007319 Avena orientalis Nutrition 0.000 description 1
244000075850 Avena orientalis Species 0.000 description 1
201000004569 Blindness Diseases 0.000 description 1
108010075254 C-Peptide Proteins 0.000 description 1
206010010071 Coma Diseases 0.000 description 1
235000019750 Crude protein Nutrition 0.000 description 1
235000000638 D-biotin Nutrition 0.000 description 1
239000011665 D-biotin Substances 0.000 description 1
201000004624 Dermatitis Diseases 0.000 description 1
240000005979 Hordeum vulgare Species 0.000 description 1
235000007340 Hordeum vulgare Nutrition 0.000 description 1
208000028389 Nerve injury Diseases 0.000 description 1
229940079172 Osmotic diuretic Drugs 0.000 description 1
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
240000006394 Sorghum bicolor Species 0.000 description 1
235000011684 Sorghum saccharatum Nutrition 0.000 description 1
235000009430 Thespesia populnea Nutrition 0.000 description 1
235000021307 Triticum Nutrition 0.000 description 1
244000098338 Triticum aestivum Species 0.000 description 1
229930003756 Vitamin B7 Natural products 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
230000009471 action Effects 0.000 description 1
229940127003 anti-diabetic drug Drugs 0.000 description 1
239000003472 antidiabetic agent Substances 0.000 description 1
238000013459 approach Methods 0.000 description 1
235000013361 beverage Nutrition 0.000 description 1
102000023732 binding proteins Human genes 0.000 description 1
108091008324 binding proteins Proteins 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
235000008429 bread Nutrition 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
230000023852 carbohydrate metabolic process Effects 0.000 description 1
235000021256 carbohydrate metabolism Nutrition 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
235000005822 corn Nutrition 0.000 description 1
230000000378 dietary effect Effects 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
235000018823 dietary intake Nutrition 0.000 description 1
235000021004 dietary regimen Nutrition 0.000 description 1
230000001882 diuretic effect Effects 0.000 description 1
229940079593 drug Drugs 0.000 description 1
230000008482 dysregulation Effects 0.000 description 1
235000013399 edible fruits Nutrition 0.000 description 1
235000013345 egg yolk Nutrition 0.000 description 1
210000002969 egg yolk Anatomy 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
210000003608 fece Anatomy 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
230000004153 glucose metabolism Effects 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
230000003902 lesion Effects 0.000 description 1
208000019423 liver disease Diseases 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
235000012054 meals Nutrition 0.000 description 1
235000013372 meat Nutrition 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
230000006371 metabolic abnormality Effects 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
244000005700 microbiome Species 0.000 description 1
230000008764 nerve damage Effects 0.000 description 1
235000019679 nutrient-rich food Nutrition 0.000 description 1
239000002337 osmotic diuretic agent Substances 0.000 description 1
238000012261 overproduction Methods 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
230000006461 physiological response Effects 0.000 description 1
235000021194 placebo diet Nutrition 0.000 description 1
230000033882 response to biotin Effects 0.000 description 1
230000028327 secretion Effects 0.000 description 1
239000000243 solution Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
235000011912 vitamin B7 Nutrition 0.000 description 1
239000011735 vitamin B7 Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

Health & Medical Sciences (AREA)
Diabetes (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Hematology (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Obesity (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

NL8104818A 1980-10-27 1981-10-26 Geneesmiddel voor het behandelen van suikerziekte en werkwijze voor de toediening van het preparaat. NL8104818A (nl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US20078480A	1980-10-27	1980-10-27
US20078480		1980-10-27

Publications (1)

Publication Number	Publication Date
NL8104818A true NL8104818A (nl)	1982-05-17

Family

ID=22743169

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NL8104818A NL8104818A (nl)	1980-10-27	1981-10-26	Geneesmiddel voor het behandelen van suikerziekte en werkwijze voor de toediening van het preparaat.

Country Status (6)

Country	Link
JP (1)	JPS5799520A (fr)
AU (1)	AU7683381A (fr)
BE (1)	BE890888A (fr)
DE (1)	DE3142590A1 (fr)
FR (1)	FR2492662A1 (fr)
NL (1)	NL8104818A (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0087863B1 (fr) *	1982-03-01	1986-05-21	Efamol Limited	Composition pharmaceutique et diététique
US20050256178A1 (en) *	2002-08-23	2005-11-17	Eggersdorfer Manfred L	Novel nutraceutical compositions comprising boitin
JP2004203863A (ja) *	2002-12-09	2004-07-22	Taisho Pharmaceut Co Ltd	抗糖尿病用組成物
JP2006089392A (ja) *	2004-09-22	2006-04-06	Tohoku Univ	生活習慣病改善食品および生活習慣病治療薬

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BE788779A (fr) *	1971-09-13	1973-01-02	Magnor Inc	Produit a base de biotine pour le traitement du diabete

1981
- 1981-10-26 NL NL8104818A patent/NL8104818A/nl not_active Application Discontinuation
- 1981-10-26 AU AU76833/81A patent/AU7683381A/en not_active Abandoned
- 1981-10-27 DE DE19813142590 patent/DE3142590A1/de not_active Withdrawn
- 1981-10-27 JP JP56171944A patent/JPS5799520A/ja active Pending
- 1981-10-27 BE BE0/206366A patent/BE890888A/fr not_active IP Right Cessation
- 1981-10-27 FR FR8120147A patent/FR2492662A1/fr active Granted

Also Published As

Publication number	Publication date
FR2492662A1 (fr)	1982-04-30
DE3142590A1 (de)	1982-08-12
BE890888A (fr)	1982-02-15
JPS5799520A (en)	1982-06-21
AU7683381A (en)	1982-05-06
FR2492662B1 (fr)	1985-04-19

Legal Events

Date	Code	Title	Description
1985-01-01	A85	Still pending on 85-01-01
1985-06-03	BV	The patent application has lapsed

Publication	Publication Date	Title
Bo et al.	2019	A high whey protein, vitamin D and E supplement preserves muscle mass, strength, and quality of life in sarcopenic older adults: A double-blind randomized controlled trial
Glynn et al.	2010	Muscle protein breakdown has a minor role in the protein anabolic response to essential amino acid and carbohydrate intake following resistance exercise
Paul et al.	2016	Inositol’s and other nutraceuticals’ synergistic actions counteract insulin resistance in polycystic ovarian syndrome and metabolic syndrome: state-of-the-art and future perspectives
JP5545424B2 (ja)	2014-07-09	高齢者の骨格筋量減少を防止又は改善するためのアミノ酸含有組成物
Bell et al.	1997	Metformin
Proietto	2017	Obesity and weight management at menopause
Dukkipati et al.	2010	Is there a role for intradialytic parenteral nutrition? A review of the evidence
Laederach‐Hofmann et al.	1999	Imipramine and diet counseling with psychological support in the treatment of obese binge eaters: A randomized, placebo‐controlled double‐blind study
CN101626696B (zh)	2016-01-20	包含糖寡聚物的营养产品
EP2397039A1 (fr)	2011-12-21	Compositions destinée à retarder la progression du diabète utilisant un extrait de Salacia oblonga
WO2000045651A1 (fr)	2000-08-10	Ingestion d'arginine et secretion d'insuline
EP1397148B1 (fr)	2006-09-20	Utilisation de chrome/biotine pour le traitement de l'hyperglycemie
McCarthy et al.	2021	Extent and prevalence of post-exercise and nocturnal hypoglycemia following peri-exercise bolus insulin adjustments in individuals with type 1 diabetes
Matyjaszek-Matuszek et al.	2018	Pharmacotherapy of obesity—state of the art
Landgraf et al.	2022	Therapy of type 2 diabetes
Aberle et al.	2021	Obesity and diabetes
Gater et al.	1992	Effects of arginine/lysine supplementation and resistance training on glucose tolerance
NL8104818A (nl)	1982-05-17	Geneesmiddel voor het behandelen van suikerziekte en werkwijze voor de toediening van het preparaat.
Palana et al.	2024	Analyzing the effects of semaglutide (Ozempic/Wegovy) on metabolism: Investigating correlations with weight reduction
KR20220157906A (ko)	2022-11-29	이나보글리플로진을 포함하는 개과 동물의 당뇨병 예방 또는 치료용 약학 조성물
CN101610790B (zh)	2012-12-05	新颖的组合物及其用途
Sugiyama et al.	2020	Type 2 diabetes remission and substantial body weight reduction achieved with metformin and a sodium-glucose cotransporter 2 inhibitor
US5846544A (en)	1998-12-08	Composition and method for reducing blood sugar levels in diabetic humans
DK3006027T3 (en)	2017-12-18	Compositions comprising amino acids for use in the treatment of systemic inflammation associated with stroke in dysphagia patients
US20100028457A1 (en)	2010-02-04	Agent for prevention or treatment of blood glucose level elevation